Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 7/20 | 1.00 |
| ▸ | EPAS1 | Q99814 | 3/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.96 |
| ▸ | LMNA | P02545 | 4/20 | 0.96 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.96 |
| ▸ | MEN1 | O00255 | 6/20 | 0.89 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.89 |
| ▸ | SLC2A1 | P11166 | 5/20 | 0.89 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.89 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.89 |
| ▸ | NPC1 | O15118 | 3/20 | 0.89 |
| ▸ | RAB9A | P51151 | 3/20 | 0.89 |
| ▸ | MAPT | P10636 | 2/20 | 0.89 |
| ▸ | STAT6 | P42226 | 2/20 | 0.89 |
| ▸ | TP53 | P04637 | 1/20 | 0.89 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.89 |
| ▸ | THPO | P40225 | 1/20 | 0.89 |
| ▸ | HTT | P42858 | 1/20 | 0.89 |
| ▸ | RBBP9 | O75884 | 1/20 | 0.89 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.89 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cephaeline SCHEMBL13912580 | 1.00 | HIF1A (1.00) | HIF1AEPAS1SMN1; SMN2LMNACYP2D6 | |
| Cephaeline SCHEMBL29380707 | 1.00 | HIF1A (1.00) | HIF1AEPAS1SMN1; SMN2LMNACYP2D6 | |
| Cephaeline SCHEMBL2518794 | 0.99 | HIF1A (0.98) | HIF1AEPAS1SMN1; SMN2LMNACYP2D6 | |
| Emetine SCHEMBL11052542 | 0.99 | HIF1A (0.98) | HIF1AEPAS1SMN1; SMN2LMNACYP2D6 | |
| Cephaeline SCHEMBL31256787 | 0.99 | HIF1A (0.98) | HIF1AEPAS1SMN1; SMN2LMNACYP2D6 | |
| Cephaeline SCHEMBL19742946 | 0.99 | HIF1A (0.98) | HIF1AEPAS1SMN1; SMN2LMNACYP2D6 | |
| Cephaeline SCHEMBL2381570 | 0.98 | HIF1A (1.00) | HIF1AEPAS1SMN1; SMN2LMNACYP2D6 | |
| Cephaeline SCHEMBL20873862 | 0.97 | HIF1A (0.93) | HIF1AEPAS1SMN1; SMN2LMNACYP2D6 | |
| Emetine SCHEMBL24499457 | 0.94 | HIF1A (1.00) | HIF1AEPAS1SMN1; SMN2LMNACYP2D6 | |
| Emetine SCHEMBL14029342 | 0.94 | HIF1A (1.00) | HIF1AEPAS1SMN1; SMN2LMNACYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 826 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026086871-A1 | ANTI-AGEING COMPOUNDS, USES THEREFOR, METHOD FOR IDENTIFYING, AND COMPOSITIONS CONTAINING | Centre for Translational Stem Cell Biology Limited (CN) | 2026-04-30 | — | — | WO | claimed |
| EP-4677612-A1 | METHODS FOR DETERMINING DRUG CANDIDATES | mosaiques diagnostics & therapeutics AG (DE) | 2026-01-14 | — | — | EP | claimed |
| CN-119233997-A | Tetrahedral antibodies | 生物分子控股有限责任公司 | 2024-12-31 | — | — | CN | claimed |
| EP-4463485-A2 | TETRAHEDRAL ANTIBODIES | Biomolecular Holdings LLC (US) | 2024-11-20 | — | — | EP | claimed |
| WO-2024213057-A1 | USE OF COMBINATION OF LSD1 INHIBITOR AND DRUG TO TREAT CANCER | 中国科学院上海药物研究所 | 2024-10-17 | — | — | WO | claimed |
| WO-2024184437-A1 | METHODS FOR DETERMINING DRUG CANDIDATES | MOSAIQUES DIAGNOSTICS AND THERAPEUTICS AG (DE) | 2024-09-12 | — | — | WO | claimed |
| EP-4428869-A1 | METHODS FOR DETERMINING DRUG CANDIDATES | mosaiques diagnostics & therapeutics AG (DE) | 2024-09-11 | — | — | EP | claimed |
| WO-2024175719-A1 | COMPOUNDS AND METHODS FOR TREATING AND/OR ALLEVIATING THE SIDE EFFECTS OF MYOCARDIAL INFARCTION | SYDDANSK UNIVERSITET (DK) | 2024-08-29 | — | — | WO | claimed |
| WO-2023219526-A1 | MULTITARGET ANTIVIRAL DIETARY SUPPLEMENT | PROKIN MILAN (RS) | 2023-11-16 | — | — | WO | claimed |
| US-20230346820-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF SARS-COV-2 | THE SCRIPPS RESEARCH INSTITUTE | 2023-11-02 | — | — | US | claimed |
| CN-1679955-A | Pharmaceutical composition capable of improving medication safety | LOTUS PHARMACEUTICAL CO LTD (CN) | 2005-10-12 | — | — | CN | claimed |
| US-20050220715-A1 | Methods and compositions for improving drug safety | LOTUS PHARMACEUTICAL CO., LTD. (TW) | 2005-10-06 | — | — | US | claimed |
| WO-2005018616-A1 | METHOD FOR DETERRING ABUSE OF OPIOIDS BY COMBINATION WITH NON-RELEASE FORMULATION OF EMETIC | ENDO PHARMACEUTICALS, INC. (US) | 2005-03-03 | — | — | WO | claimed |
| WO-2005004989-A2 | FILM COMPRISING THERAPEUTIC AGENTS | MAIBACH TODD (US) | 2005-01-20 | — | — | WO | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| US-4529583-A | Composition and method of immobilizing emetics and method of treating human beings with emetics | CLEAR LAKE DEVELOPMENT GROUP (US) | 1985-07-16 | — | — | US | claimed |
| US-4459278-A | Composition and method of immobilizing emetics and method of treating human beings with emetics | CLEAR LAKE DEVELOPMENT GROUP (US) | 1984-07-10 | — | — | US | claimed |
| US-4175119-A | Composition and method to prevent accidental and intentional overdosage with psychoactive drugs | PORTER GARRY L | 1979-11-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230346820-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF SARS-COV-2 | ACE2, SARS1, ACE | HIF1A 2031/4885EPAS1 2738/4885SMN1; SMN2 2055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.